Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.
Annals of Oncology（2022）
摘要
Neoadjuvant FOLFIRINOX is an active regimen for patients with LA/BR PDAC with a resection rate of 22.5%. These results are in line with prior data.
更多查看译文
关键词
FOLFIRINOX,neoadjuvant therapy,pancreatic neoplasm,resectability,survival
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要